Alexion's Soliris Could Benefit From Japan's Orphan Drug Pricing Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S.-based Alexion Pharmaceuticals has orphan designation in Japan for Soliris (eculizumab) for patients with rare paroxysmal nocturnal hemoglobinuria blood disorder.
You may also be interested in...
Japan's MHLW Enhances Role Of Innovation In Drug Pricing, USTR Says
WASHINGTON - Japan is giving more weight to innovation when pricing new drugs
Alexion Aims To Drive PNH Diagnoses (And Soliris Sales) With Diagnostic
Alexion believes the challenge of identifying new patients with the "ultra-orphan" blood disorder paroxysmal nocturnal hemoglobinuria who are candidates for the company's biologic Soliris (eculizumab) will be helped by diagnostic technology recently in-licensed by the firm
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.